At present, there is no exact method for the transformation of hepatitis B to negative in the world. It is more difficult to turn Triple Triple Yang into negative, most Triple Triple Yang patients are still positive for Hepatitis B surface antigen after treatment, but they can be clinically cured through treatment.
Clinical anti-Hepatitis B virus therapy can enable a small number of patients with triple-A virus to turn negative. Antiviral drugs include interferon or nucleoside analogs, such as entecavir and tenofovir. According to statistics, the conversion rate is about 3% after 48 weeks of antiviral therapy with pegylated interferon alpha-2a, and 2%-3% after 48 weeks-52 weeks of entecavir or tenofovir.
A very small number of patients with good resistance may also develop protective antibodies over time after they have completely cleared the virus, realizing the conversion rate, and the annual incidence of this situation is only 0.5%-1%.
Most of the patients with hepatitis B in the clinic are still in the state of hepatitis B virus carrier even after active antiviral treatment, and the surface antigen of hepatitis B is still positive.
Whether hepatitis B infected patients need antiviral treatment is mainly determined by checking liver function, hepatitis B virus DNA, liver elasticity and liver hardness, etc. After treatment, those whose hepatitis B virus DNA reaches the standard of reference value and whose liver function recovers can be regarded as clinically cured.